Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Herpes Virus C5252 Injection in Patients With Intracranial Tumor

NCT07243340 is registered in ClinicalTrials.gov with ImmVira Pharma Co. Ltd as lead sponsor.

NCT NCT07243340
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07243340 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Herpes Virus C5252 Injection in Patients With Intracranial Tumor
Lead sponsor
ImmVira Pharma Co. Ltd
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 3, 2026
Completion date
December 15, 2028
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioma, malignant